These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25882985)

  • 1. Targeting the microenvironment in ovarian cancer.
    Lheureux S; Oza AM
    Lancet Oncol; 2015 May; 16(5):485-6. PubMed ID: 25882985
    [No Abstract]   [Full Text] [Related]  

  • 2. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
    Safra T; Andreopoulou E; Levinson B; Borgato L; Pothuri B; Blank S; Tiersten A; Boyd L; Curtin J; Muggia F
    Anticancer Res; 2010 Sep; 30(9):3243-7. PubMed ID: 20944093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib: a new drug for pancreatic neuroendocrine tumours.
    Kwekkeboom DJ
    Lancet Oncol; 2015 Jun; 16(6):606-7. PubMed ID: 25956796
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
    Zvaríková M
    Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Miura H; Shirai H
    Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
    [No Abstract]   [Full Text] [Related]  

  • 7. Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
    Nishikawa T; Hasegawa K; Yabuno A; Yoshida H; Yasuda M; Kozawa E; Fujiwara K
    J Gynecol Oncol; 2017 Jan; 28(1):e25. PubMed ID: 27958685
    [No Abstract]   [Full Text] [Related]  

  • 8. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
    Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and Pazopanib in Ovarian Cancer.
    Tomao F; Benedetti Panici P; Tomao S
    JAMA Oncol; 2018 Sep; 4(9):1298-1299. PubMed ID: 29978181
    [No Abstract]   [Full Text] [Related]  

  • 10. Paclitaxel and Pazopanib in Ovarian Cancer-Reply.
    Richardson DL; Coleman RL; Sill MW
    JAMA Oncol; 2018 Sep; 4(9):1299. PubMed ID: 29978183
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 12. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.
    Kaye SB
    Int J Gynecol Cancer; 2005; 15 Suppl 1():31-5. PubMed ID: 15839956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
    J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
    Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
    Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
    Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
    Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.